The global stable angina management market is on a robust growth trajectory, expected to reach US$ 11 billion in 2023 and US$ 25.1 billion by 2033. This growth reflects a compound annual growth rate (CAGR) of 8.6% during the forecast period from 2023 to 2033. The market demonstrated a CAGR of 5.2% in the historical period from 2018 to 2022.
Stable angina, characterized by chest pain or discomfort due to reduced blood flow to the heart, necessitates effective management strategies. The increasing prevalence of cardiovascular diseases, combined with a growing awareness of the importance of heart health, is driving demand for innovative treatment options.
Pharmaceutical products play a crucial role in managing stable angina. Commonly used treatments include antiplatelet agents, such as aspirin and clopidogrel, which help prevent blood clots, and nitroglycerin, which relaxes and widens blood vessels to improve blood flow. Additionally, beta-blockers, calcium channel blockers, and ACE inhibitors are frequently prescribed to manage symptoms and improve patient outcomes.
As healthcare providers continue to prioritize effective management strategies for stable angina, the market is expected to see significant advancements and innovations in treatment options, enhancing patient care and improving quality of life.
Medical devices used for the management of stable angina include stents, which are small mesh tubes that are inserted into narrowed or blocked arteries to improve blood flow, and coronary artery bypass surgery (CABG), which involves rerouting blood flow around a blocked or narrowed artery.
The stable angina management market is driven by factors such as the growing prevalence of cardiovascular diseases, increasing adoption of advanced medical technologies, and rising healthcare expenditure. However, the market may face challenges such as the availability of alternative treatment options, high cost of some treatments, and limited access to healthcare in certain regions.
Which are Some Prominent Drivers of the Stable Angina Management Market?
Increasing Prevalence of Cardiovascular Diseases to Push Market Growth
The rising prevalence of cardiovascular diseases is expected to be one of the major drivers pushing the growth of the stable angina management market. Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels, and they are among the leading causes of death and disability worldwide. Stable angina is one of the most common forms of CVDs.
According to a report by the World Health Organization (WHO), CVDs are the leading cause of death globally, with an estimated 17.9 million deaths annually. The report also highlights that four out of five CVD deaths are due to heart attacks and strokes, which are often caused by a blockage that prevents blood flow to the heart or brain.
As the prevalence of CVDs continues to rise globally, the demand for effective treatment options for stable angina is also expected to increase. This is likely to drive the growth of the stable angina management market, as more patients seek medical interventions to manage their condition.
Moreover, the increasing incidence of risk factors for CVDs, such as high blood pressure, high cholesterol, obesity, and diabetes, is also contributing to the rise in CVDs. This is expected to further increase the demand for stable angina management products and services.
Overall, the rising prevalence of CVDs, along with increasing awareness and a growing demand for effective treatment options, is expected to push the growth of the stable angina management market in the coming years.
Market Competition
Key players in the market include companies such as Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc. along with healthcare providers and technology companies among other global players.
- In Early 2022, Health Canada granted approval for Corzyna as an additional therapy for patients suffering from stable angina who do not respond well to or cannot tolerate first-line therapies. Corzyna is considered a second-line therapy and is more expensive than the current treatment options for angina, with an annual cost of $2,555. This medication is recommended to be placed under Special Authorization for ClaimSecure groups subscribing to Managed Plans to ensure it is reserved for patients who have tried or are intolerant to more cost-effective options, while it will be fully covered for groups subscribing to Open Formularies.
Corzyna is a new medication that has been found to decrease the occurrence of angina attacks when used with first-line agents like beta-blockers and calcium channel blockers, as compared to the use of first-line therapies alone. In addition, for those who are intolerant to first-line therapy, Corzyna can be added to lower the dose of first-line therapy, thereby reducing the risk of undesirable side effects such as low blood pressure or heart rate.
Key Companies Profiled
Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc.
Key Segments Profiled in the Stable Angina Management Industry Survey
Drug Class:
- Beta Blockers
- Calcium Antagonists
- Anti-coagulants
- Antiplatelets
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
